Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct;195(3):441-451.
doi: 10.1007/s10549-022-06709-x. Epub 2022 Aug 20.

Treatment of HR+/HER2- breast cancer in urban mainland China: results from the CancerMPact Survey 2019

Bhavna Murali  1 , Laura Durbin  2 , Sapna Vijaykumar  2 , Linda Yang  2 , Song Li  2 , Linda Zhao  2 , Stephanie Hawthorne  2 , Gena Kanas  2 , Christine Davis  2 , Otávio Clark  2
Affiliations

Treatment of HR+/HER2- breast cancer in urban mainland China: results from the CancerMPact Survey 2019

Bhavna Murali et al. Breast Cancer Res Treat. 2022 Oct.

Abstract

Purpose: To report the treatment utilization patterns for hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer in urban mainland China (CancerMPact®).

Methods: The results presented are from an online survey conducted in September 2019 with 45 physicians treating breast cancer patients from 11 cities in mainland China.

Results: Surveyed physicians reported that Stage I HR+/HER2(-) breast cancer patients are often treated with surgery alone (42%), whereas the use of surgery in combination with systemic therapy with or without radiotherapy increases in later stages (Stage II 67%, Stage III 77%). Doxorubicin-cyclophosphamide (AC)-based regimens were the most common in both the neoadjuvant and adjuvant settings in HR+/HER2(-) breast cancer patients, across all stages. In metastatic patients, use of surgery and radiotherapy decreases in favor of utilization of systemic therapy alone. Pre- and post-menopausal metastatic patients were frequently treated with hormone therapy or AC-based regimens in first line. Regardless of the first-line therapy administered, capecitabine-based regimens were commonly used in second line. In third line, chemotherapy regimens containing capecitabine or gemcitabine were given to nearly 40% of HR+/HER2(-) breast cancer patients. There were no standard of care regimens established for fourth or greater lines of treatment. In metastatic HR+/HER2(-) breast cancer, physicians reported 50% objective response rates in first-line settings with a progression-free survival of 16 months.

Conclusion: HR+/HER2(-) breast cancer patients in urban mainland China were prescribed chemotherapy regimens more frequently than CDK4/6 inhibitors. Treatment practices varied, with physicians reporting the use of multiple modalities and treatment regimens for their patients.

Keywords: Breast cancer; Cancer treatment; Chemotherapy; China; Treatment patterns.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

References

    1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi: 10.3322/caac.21660. - DOI - PubMed
    1. Feng RM, Zong YN, Cao SM, Xu RH. Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics? Cancer Commun (Lond) 2019;39(1):22. doi: 10.1186/s40880-019-0368-6. - DOI - PMC - PubMed
    1. CancerMPact® Database (2021), Kantar, www.cancermpact.com.
    1. Francies FZ, Hull R, Khanyile R, Dlamini Z. Breast cancer in low-middle income countries: abnormality in splicing and lack of targeted treatment options. Am J Cancer Res. 2020;10(5):1568–1591. - PMC - PubMed
    1. Valla M, Vatten LJ, Engstrøm MJ, et al. Molecular subtypes of breast cancer: long-term incidence trends and prognostic differences. Cancer Epidemiol Biomarkers Prev. 2016;25(12):1625–1634. doi: 10.1158/1055-9965.EPI-16-0427. - DOI - PubMed